Co-Diagnostics, Inc. (CODX) · Oct 13, 2026 · New debt
Debt secured — $2.1M cash versus $2.835M repayment obligation over 30 weeks
Co-Diagnostics secured a $2.1 million loan, but steep weekly repayments, ATM cash control and conversion terms materially tighten its financing.
Co-Diagnostics is a cash-constrained molecular-diagnostics company still developing its Co-Dx PCR point-of-care platform and multiplex respiratory testing strategy, while its main commercial base remains comparatively small. The latest public quarter showed $3.6 million of cash at June 30, 2026, underscoring why this financing matters for near-term operations.
| Financing term | Filing detail |
|---|---|
| Initial cash funded | $2.1 million (Loan Agreement) |
| Net initial proceeds | Approximately $2.016 million after 4% origination fee (Loan Agreement) |
| Original principal owed | $2.835 million (Initial Note) |
| Scheduled repayment | 30 weekly installments of $94,500 (Section 2.07) |
| Potential additional borrowing | $1.0 million, with a $1.35 million note (Loan Agreement) |
| Minimum unrestricted cash | $250,000 (Minimum Cash Requirement) |
| ATM capacity subject to waterfall | $7.35 million (Section 3.01(jj)) |
The financing solves an immediate cash problem, but at an expensive effective cost. Co-Diagnostics receives roughly $2.016 million after the origination fee, yet must repay $2.835 million through 30 weekly payments of $94,500. 〔0〕 That is not flexible growth capital: it creates a roughly $94,500 weekly cash obligation before considering the placement fee, operating expenses, or any additional borrowing. The company says the proceeds are for general working capital, not a specifically identified product launch or revenue-generating investment. 〔1〕
The key change is that the lender now sits between the company and its ATM cash. All ATM proceeds must flow into a controlled account, with the first $1.0 million going to the lender and 80% of proceeds initially applied to the notes. 〔2〕 This gives Co-Diagnostics access to liquidity, but not full discretion over it; the financing effectively depends on continued equity sales to service debt.
The debt is secured by nearly the entire operating business and can become equity-linked if execution slips. The lender receives a senior-priority lien on substantially all assets, guarantees from the subsidiaries, 600,000 commitment shares, and conversion rights at a discount to recent trading prices. If the company defaults, the balance rises to 120% of principal, carries 19% compounded daily interest, and can convert at 80% of the lowest recent VWAP.
The agreement also forces a near-term corporate-action timetable. Co-Diagnostics must seek approval for expanded share issuance and reverse-split authority, with the stockholder meeting required by November 10, 2026; failure to obtain the reverse-split approval is itself an event of default. That makes shareholder approval and Nasdaq compliance part of the financing mechanics, not merely routine governance.
Bottom line: This is emergency-style liquidity rather than a clean funding win. It extends operating runway, but the high-cost weekly amortization, ATM cash sweep, broad collateral package and equity-conversion provisions materially tighten Co-Diagnostics’ room to execute its diagnostics strategy without further financing or shareholder action.
Stockholder meeting required by November 10, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!